Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy.

ABSTRACT: Tumor vaccines are emerging as one of the most promising therapeutic strategies for cancer treatment. With the advantages of low toxicity, convenient production and stable quality control, peptide vaccines have been widely used in preclinical and clinical trials involving various malignancies. However, when used alone, they still suffer from significant challenges including poor stability and immunogenicity as well as the low delivery efficiency, leading to limited therapeutic success. Herein, the STING-activating peptide nanovaccine based on human serum albumin (HSA) and biodegradable MnO₂ was constructed, which can improve the stability and immunogenicity of antigenic peptides as well as facilitate their uptake by dendritic cells (DCs). Meanwhile, Mn²⁺ degraded from

SUBMITTER: Zheng A 

PROVIDER: S-EPMC10835291 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature